Cell No. : Cell Name
RCB1169 : TGBC18TKB
update : 2022/07/20
|
| Comment | Papillotubular adenocarcinoma of the Vater's papilla. Application consideration |
| Comment from the depositor | |
| Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
Ohno, T. & Todoroki, T.
|
| Originator |
Kim, B. & Ohno, T.
|
| Year of deposit |
1995
|
| Another name |
UcFu
|
| Animal |
_human
< Mammals
|
| Genus |
Homo
|
| Species |
sapiens
|
| Race |
Japanese
|
| Gender |
Female
|
| Age at sampling |
79 years
|
| Tissue |
duodenum
|
| Disease name |
papillotublar adenocarcinoma
|
| Classification |
cancer
|
| Year of origin |
1995
|
|
Lifespan |
infinite
|
| Morphology |
epithelial-like
|
| Cellosaurus(Expasy) |
CVCL_3338
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Adherent cells
|
| Culture medium |
|
DMEM (low glucose) + 5% FBS
|
| Antibiotics |
|
Free
|
|
Passage method |
|
0.25% Trypsin
|
Culture information
|
Passage ratio |
|
1 : 4 split
|
| SC frequency |
|
Subculture : once/1-2 weeks, Medium Renewal : 2 times/week
|
| Temperature |
|
37
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
|
Medium + 10% DMSO
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma/Acholeplasma |
|
(-)
|
| Virus (HIV) |
|
(-)
|
| Isozyme |
|
LD, NP
|
| Chromosome mode |
|
57-63(50) : 57(3),58(39,59(7),60(19),61(10),62(5)/
|
| STR(human) |
|
OK
|
| Reference information |
Reference |
1
|
| User's Publication |
9
|
| User's Publication |
|
22703
Triboulet R, Sadykov K, Harvey DM, Wilson DM, Steinbaugh MJ, Mayo CB, Hawley D, Madanjian A, Fyfe C, Bracken C, Rivera-Rivera I, Ericsson A, Snyder AR, Knutson SK, Stein RL, Gibaja V, Ghosh S, Campbell RM.
Targeting the Synthetic Lethal Relationship between FOCAD and TUT7 Represents a Potential Therapeutic Opportunity for TUT4/7 Small-Molecule Inhibitors in Cancer
Mol Cancer Ther
2024
23(12):1779-1788
PubMed ID: 39235218
DOI: 10.1158/1535-7163.MCT-24-0176
|
|
13465
Wang CY, Chao YJ, Chen YL, Wang TW, Phan NN, Hsu HP, Shan YS, Lai MD.
Upregulation of peroxisome proliferator-activated receptor-α and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer
Int J Med Sci
2021
18(1):256-269
PubMed ID: 33390794
DOI: 10.7150/ijms.48123
|
|
13152
Cheng LC, Chao YJ, Wang CY, Phan NN, Chen YL, Wang TW, Hsu HP, Lin YJ, Shan YS, Lai MD.
Cancer-Derived Transforming Growth Factor-β Modulates Tumor-Associated Macrophages in Ampullary Cancer.
Onco Targets Ther
2020
PubMed ID: 32821120
DOI: 10.2147/OTT.S246714
|
|
3738
Yamashita-Kashima Y, Yoshimura Y, Fujimura T, Shu S, Yanagisawa M, Yorozu K, Furugaki K, Higuchi R, Shoda J, Harada N.
Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody-cytotoxic drug conjugate.
Cancer Chemother Pharmacol.
2019
83(4):659-671
PubMed ID: 30659304
DOI: 10.1007/s00280-019-03768-8
|
|
3727
Yeung Y, Lau DK, Chionh F, Tran H, Tse JWT, Weickhardt AJ, Nikfarjam M, Scott AM, Tebbutt NC, Mariadason JM
K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines.
Mol Oncol
2017
11(9):1130-1142
PubMed ID: 28544747
DOI: 10.1002/1878-0261.12078
|
|
14930
Takahashi N, Aoyama F, Hiyoshi M, Kataoka H, Sawaguchi A.
Establishment and biological characterization of a novel cell line derived from hepatoid adenocarcinoma originated at the ampulla of Vater
Int J Oncol
2014
44(4):1139-45
PubMed ID: 24481592
DOI: 10.3892/ijo.2014.2282
|
|
19029
Kanamori-Katayama M, Kaiho A, Ishizu Y, Okamura-Oho Y, Hino O, Abe M, Kishimoto T, Sekihara H, Nakamura Y, Suzuki H, Forrest AR, Hayashizaki Y.
LRRN4 and UPK3B are markers of primary mesothelial cells
PLoS One
2011
6(10):e25391
PubMed ID: 21984916
DOI: 10.1371/journal.pone.0025391
|
|
19308
Taniguchi H, Yamamoto H, Akutsu N, Nosho K, Adachi Y, Imai K, Shinomura Y.
Transcriptional silencing of hedgehog-interacting protein by CpG hypermethylation and chromatic structure in human gastrointestinal cancer
J Pathol
2007
213(2):131-9
PubMed ID: 17724792
DOI: 10.1002/path.2216
|
|
3713
Taniguchi H, Yamamoto H, Hirata T, Miyamoto N, Oki M, Nosho K, Adachi Y, Endo T, Imai K, Shinomura Y.
Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers.
Oncogene
2005
24(53):7946-52
PubMed ID: 16007117
DOI: 10.1038/sj.onc.1208910
|
Back
Top
CELL BANK Website